Interferon News and Research

RSS

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.

2 Jun 2020

Specific immune suppression leads to severe COVID-19 disease

A new study published online on the preprint server medRxiv in May 2020 reports that specific changes in the way the human immune system responds to COVID-19 determine whether the individual develops moderate or severe illness.

2 Jun 2020

Study: Glucocorticoids are harmful for patients suffering from viral respiratory infections

Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS) despite there being no indisputable scientific evidence of their effectiveness.

29 May 2020

New drug combinations could help overcome genetic immunotherapy resistance

A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

28 May 2020

Many different T cell receptors recognize SARS-CoV-2 antigenic sites

The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading over the world. However, not much is known about how the adaptive immune response kicks in following the viral challenge. This knowledge is crucial to predicting the efficacy of a vaccine and estimating the chances of reinfection.

26 May 2020

Researchers identify genetic mechanisms that produce radioresistance in cancer cells

Cancer stem cells are a cell type that was previously little known. They are resistant to irradiation and prevent the effective treatment of many types of cancer. A research group from Innsbruck has now identified two genetic mechanisms that produce this radioresistance.

26 May 2020

Children with COVID-19 presenting with sudden severe lung disease

Even as the COVID-19 pandemic continues to seek out new victims, puzzling new presentations are further confusing the situation. A new study published online in The Lancet Rheumatology in May 2020 reports a case of severe COVID-19 in a child who rapidly developed acute respiratory distress symptoms without prior respiratory symptoms. This case should alert clinicians to consider this diagnosis in children as well.

24 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Producing virus-specific antibodies after COVID-19

In order to design effective vaccines for COVID-19, we need to understand our immune responses. News-Medical speaks to Professor Chen Dong to find out more.

21 May 2020

Smoking increases ACE2 protein in the lungs which may promote COVID-19 infection

Previous data from COVID-19 patients suggests that cigarette smokers are more likely to have health complications.

18 May 2020

People with Hepatitis D have up to three times the risk of developing fatal liver cancer

Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

Roswell Park team proposes possible new strategy for treating pancreatic cancer

A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology.

18 May 2020

People infected with hepatitis D are more prone to hepatocellular carcinoma

Of all the hepatitis viruses, D is the most poorly known.This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

Antiviral drug can help accelerate recovery of COVID-19 patients, study shows

An international team of researchers led by Dr. Eleanor Fish, emerita scientist at the Toronto General Hospital Research Institute, University Health Network, and professor in the University of Toronto's Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.

15 May 2020

Antiviral agent accelerates virus clearance in cases of COVID-19

A team of researchers from have found an antiviral therapy that seems to be an effective treatment for patients with moderate coronavirus disease 2019 (COVID-19).

15 May 2020

Researchers identify CoV Mac1 proteins as a potential SARS-CoV-2 drug target

A recent study by researchers at the University of Kansas and published on the preprint server bioRxiv* reveals that Mac1 protein implicated in the infection process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a strikingly similar structure and activity in all coronaviruses – suggesting that possible future treatments targeting this protein may exert broad antiviral activity.

13 May 2020

Clinical trial to evaluate two-drug immunotherapy combination in cancer patients with COVID-19

A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.

12 May 2020

Potential for COVID-19 transmission from human eye

A new study published on the preprint server bioRxiv* in May 2020 reports the presence of ACE2 receptors in the eye at high concentrations. These molecules are the entry points for the SARS-CoV-2 virus that is causing the ongoing COVID-19 pandemic.

12 May 2020

Antiviral cocktail may help treat mild COVID-19 patients

The skyrocketing number of cases due to the coronavirus pandemic has taken a massive toll on the health systems in many countries. Since the advent of the coronavirus disease (COVID-19), hundred of research teams are racing to find an effective vaccine and treatment to combat the deadly infection. Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients.

12 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020